Inventor
MARTINI PAOLO
US23 patents
⚠️ This page may combine multiple inventors who share the name “MARTINI PAOLO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MODERNATX INC
14 patentsUS11504337B2Nov 22, 2022
Polynucleotides encoding methylmalonyl-CoA mutase
MODERNATX INC12 citations86
US11001861B2May 11, 2021
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
MODERNATX INC11 citations84
US10426738B2Oct 1, 2019
Polynucleotides encoding methylmalonyl-CoA mutase
MODERNATX INC5 citations84
US10406112B2Sep 10, 2019
Polynucleotides encoding methylmalonyl-CoA mutase
MODERNATX INC7 citations84
US11649461B2May 16, 2023
Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease
MODERNATX INC1 citations71
US10993918B2May 4, 2021
Polynucleotides encoding citrin for the treatment of Citrullinemia type 2
MODERNATX INC2 citations71
US10519455B2Dec 31, 2019
Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
MODERNATX INC1 citations71
US10494636B2Dec 3, 2019
Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease
MODERNATX INC3 citations71
US11801227B2Oct 31, 2023
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
MODERNATX INC1 citations62
US12252704B2Mar 18, 2025
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
MODERNATX INC0 citations61
US12239742B2Mar 4, 2025
Polynucleotides encoding Citrin for the treatment of Citrullinemia type 2
MODERNATX INC0 citations61
US12128113B2Oct 29, 2024
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
MODERNATX INC0 citations61
US12377136B2Aug 5, 2025
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
MODERNATX INC0 citations59
US12123030B2Oct 22, 2024
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
MODERNATX INC0 citations52
SHIRE HUMAN GENETIC THERAPIES
4 patentsUS9814764B2Nov 14, 2017
Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidase
SHIRE HUMAN GENETIC THERAPIES9 citations90
US9206235B2Dec 8, 2015
Peptide linkers for polypeptide compositions and methods for using same
SHIRE HUMAN GENETIC THERAPIES8 citations82
US11065307B2Jul 20, 2021
Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety
SHIRE HUMAN GENETIC THERAPIES2 citations81
US9932568B2Apr 3, 2018
Peptide linkers for polypeptide compositions and methods for using same
SHIRE HUMAN GENETIC THERAPIES2 citations71